Newsletter Summary: Successful China-UK Biopharmaceutical Forum
We are delighted to announce that the China-UK Biopharmaceutical Exchange and Seminar Forum was held in Beijing on June 27, 2024. The event was led by the Chairman of the 48 Group, Jack Perry, who, along with a distinguished delegation from the UK headed by Sir Christopher Evans, discussed vital topics in life sciences and biotechnology. Sir Christopher Evans is a leading figure in the UK, renowned for his contributions to life sciences and biotechnology.
The forum was a great success, resulting in several strategic agreements. The 48 Group will be establishing a platform and incubator in Beijing to facilitate cooperation in fields such as biomedicine, intelligent manufacturing, and information technology. This initiative will also include the setup of cooperation funds, aiming to foster innovation and collaboration.
If your company is interested in healthcare and life sciences, there is now a unique opportunity to get involved and invest both ways, enhancing international cooperation and development in these cutting-edge fields. Contact for more info at events@the48groupclub.com
Strategic Cooperation Agreement Signed Between Beijing Economic-Technological Development Area and UK 48 Group
Source: Yicheng Times | Date: June 28, 2024, 11:47 AM
On June 27, during the China-UK Biomedical Exchange and Seminar Forum, Beijing Economic-Technological Development Area (BDA) and the UK 48 Group officially signed a strategic cooperation agreement.
Specifically, Beijing BDA will collaborate with the UK 48 Group to establish an incubation platform focusing on fields such as biomedicine, intelligent manufacturing, information technology, and cultural sports, promoting the implementation of various cooperative outcomes. The partnership will also organize industrial summits and forums to help local enterprises connect with international resources. Additionally, Beijing BDA supports the UK 48 Group in establishing a main office within the area, aiding local enterprises in expanding international business and assisting companies with financing needs in accessing global financing channels.
Established in 1954, the UK 48 Group has long been dedicated to promoting China-UK trade and cultural exchanges, with significant influence in business, culture, and academia. “Leveraging this agreement, we will advance comprehensive cooperation in areas such as setting up cooperation funds, incubating enterprises, establishing operational entities, and organizing industrial forums, all based on our own industrial layout and the platform advantages of the UK 48 Group,” said a Beijing BDA official. This cooperation is expected to create more opportunities and conditions for local enterprises to expand into the UK and overseas markets, accelerating the construction of the “Two Zones” and enhancing the internationalization level of Beijing BDA.
The official added, “British enterprises have always been important partners in deepening high-level openness in BDA. This cooperation marks another milestone in promoting China-UK collaboration.” Currently, Beijing BDA hosts over 1,300 foreign-funded enterprises from 62 countries and regions, with 158 projects invested by 103 Fortune 500 companies, of which one-quarter of the British Fortune 500 companies have projects in cooperation with BDA.
Since the beginning of this year, representative foreign enterprises and projects, such as the start of operations for the Steinbeis Technology Management Headquarters and the inauguration of the regional headquarters of Varian Medical Systems, have chosen BDA, thanks to its comprehensive policy system and world-class business environment. To enhance foreign investment attraction, Beijing BDA has introduced a “2+X” policy system, providing substantial support for the establishment of multinational company headquarters and foreign-funded R&D centers. Additionally, BDA continues to optimize services for foreign enterprises, upgrading the “One-Stop Foreign Affairs Service” and conducting special actions like Foreign Enterprise Open Days, roundtable forums, and foreign trade service outreaches. The area has also launched hotlines for foreign trade enterprises and international talent, implementing plans to find markets, recruit talent, and seek partners for foreign enterprises, creating a welcoming service brand.
Invitations Sent to Promote Five Biopharmaceutical Companies Onsite
“We hope to explore broader cooperation spaces with investment institutions, investors, and clinical institutions in the UK and globally to achieve win-win development,” said Xie Liangzhi, Chairman of Beijing Shenzhou Cell Biotechnology Group Co., Ltd., expressing the sentiments of many local enterprises.
On the afternoon of June 27, the 2024 China-UK Biomedical Exchange and Seminar Forum was held. At this event, which attracted over 200 experts, scholars, and business representatives from home and abroad, five local companies—Shenzhou Cell, Synovation Medical, Centron Pharma, Yibo Biotech, and Qianglian Zhichuang—promoted themselves onsite, showcasing their strengths and reaching a consensus through dialogue.
Chairman Xie Liangzhi of Shenzhou Cell introduced the significant changes in the Chinese biopharmaceutical industry from 1990 to 2024 and highlighted the company’s innovative achievements since its founding in 2002. In 2021, Shenzhou Cell’s independently developed hemophilia treatment drug Anjain®️ (recombinant human coagulation factor VIII) was launched, breaking the long-standing monopoly of imported products in the domestic hemophilia treatment field. This marked an enhancement in China’s biopharmaceutical R&D and innovation capabilities and reshaped the hemophilia treatment landscape in China.
Representing the robust growth of local biopharmaceutical enterprises, Beijing BDA has cultivated many quality biopharmaceutical companies driving the progress of China’s healthcare industry. Onsite, Fu Shinong, General Manager of Synovation Medical, introduced the company’s comprehensive CT product solutions, including China’s first domestically developed conventional large-aperture diagnostic-grade CT series, the first full-body standing spiral CT, and high-definition weight-bearing joint CT. “Currently, our CT products have been exported to over 50 countries worldwide, with Europe being our next key market for expansion. We look forward to collaborating with all of you,” said Fu.
Wang Peng, Vice President of Centron Pharma, focused on the theme “Based in China, Looking Globally: Key Player in the Radiopharmaceutical Market,” introducing the broad prospects of radiopharmaceuticals and Centron Pharma’s strengths and achievements in this field. Global radiopharmaceuticals are primarily used in the fields of neurology, cardiovascular, and oncology. As a leading innovative radiopharmaceutical company in China, Centron Pharma has been developing the next generation of radiopharmaceuticals since 2014, and currently has more than 20 precision diagnostics and targeted treatment radiopharmaceuticals in its pipeline.
Wang Yangzhou, General Manager of Yibo Biotech, focused on the company’s engineered DC cell immunotherapy technology. Qin Lan, Founder and Chairman of Qianglian Zhichuang, introduced the core product—an AI-driven next-generation neurointerventional surgery “autopilot” solution, detailing its core technology, application scenarios, and market prospects.
The innovative achievements and robust growth of these biopharmaceutical companies represent the foundation of Beijing BDA’s push for China-UK cooperation. Currently, Beijing BDA has gathered over 4,200 pharmaceutical and health companies, covering all key links in the entire industrial chain from innovative R&D to technology transfer and industrialization, establishing a comprehensive service system for the biopharmaceutical industry.
Promoting Exchange: Delegation Visits Local Biopharmaceutical Companies
The AI orthopedic surgery robot attracted the delegation’s attention. (Photo by Li Xiao)
On the morning of June 27, Jack Perry, Chairman of the UK 48 Group, and Sir Christopher Evans, along with their delegation, visited three representative biopharmaceutical companies in Beijing BDA. They also experienced autonomous driving vehicles, witnessing the cutting-edge technological achievements of Beijing BDA, laying a solid foundation for China-UK cooperation in the biopharmaceutical field through in-depth exchanges.
At Yibo Biotech, the UK 48 Group delegation visited the company’s exhibition hall and laboratory, learning in detail about the company’s development history and technological achievements. Yibo Biotech has advanced engineered DC cell immunotherapy technology and has built a human DC cell resource bank, focusing on creating a collaborative life science industry platform integrating production, education, research, and application. This platform conducts new drug development, cell storage and preparation, technological services, personalized precision medicine, and health management. Yibo Biotech representatives introduced the multiple application scenarios and commercial potential of engineered DC cell immunotherapy technology and discussed cooperation and development in the China-UK biopharmaceutical field.
The delegation then visited Yongtai Biopharmaceuticals, gaining insights into its core products and R&D and production layout through on-site visits and briefings. Yongtai Biopharmaceuticals representatives introduced their nearly 30,000-square-meter GMP-standard cell immunotherapy product intelligent manufacturing plant in Beijing BDA, which addresses key technical challenges in large-scale production and quality control in China’s cell therapy industry, achieving fully enclosed and large-scale production of immunotherapy drugs.
At Changmugu, the AI orthopedic surgery robot attracted the delegation’s attention. Changmugu representatives introduced the company’s growth and the application of its AI orthopedic surgery robot. The delegation showed great interest and experienced the simulated operation of the ROPA orthopedic surgery robot assisting in knee replacement surgery, experiencing firsthand the revolutionary changes AI technology brings to traditional complex surgeries.
This in-depth visit is expected to drive a new round of cooperation. During the visit, the UK 48 Group and the heads of the three companies discussed the next steps for collaboration, expressing their hopes to work together with Beijing BDA and its high-quality enterprises to promote technological exchanges and cooperation in the China-UK biopharmaceutical field.
For original article see here